Preoperative tests can only be justified if they reveal actionable data that alters clinical management in a way that improves patient safety and outcomes. A recent Cochrane review of three randomized trials including over 21,000 cataract surgeries concluded that pre-operative testing does not reduce the risk of intraoperative or postoperative adverse events compared to no testing. Other studies indicate that routine testing, especially in patients without significant systemic disease undergoing low risk procedures, often does not change perioperative management, may lead to follow-up testing and invasive interventions with normal results, and can unnecessarily delay surgery or other procedures. Because they do not alter clinical management or improve patient outcomes, we define routine preoperative testing of any patients before cataract surgery and routine preoperative testing of patients without significant systemic disease undergoing other low-risk procedures as low value tests.
In order to ensure that VHA patients receive the highest value care, are not subjected to low value testing with little or no benefit and potential unintended harm, and to ensure that VHA uses its resources to produce the largest possible positive impact on health outcomes, this study aims to describe the burden of low value testing within VHA and understand drivers of low value testing. If patterns of low value preoperative testing are found within VHA, an important practice improvement or "de-implementation" target exists that could afford significant opportunities to redirect resources to other organizational priorities, such as improved access and the provision of evidence-supported treatments.
Aim 1: Describe system-wide and facility-level rates and associated costs of low value pre-operative testing in the 30 and 60 days before high-frequency low-risk procedures including cataract surgery (>50,000 annually), carpal tunnel release (>9,500 annually), and upper and lower digestive tract endoscopy (>500,000 annually).
Aim 2: Examine the patient factors (e.g., comorbidities), clinician factors (e.g., ordering clinician specialty), and facility-level factors (e.g., surgical volume) that may be associated with the ordering of low value preoperative tests.
Aim 3: Identify VHA sites with the highest rates and total expenditures on low value pre-operative testing in common low risk procedures, as well as sites that have recently switched from high to low use of low value testing. Using the Theoretical Domains Framework (TDF), we will interview key informants at these sites in order to understand which TDF constructs are drivers of low value testing, as well as barriers to and facilitators of de-implementing low value tests.
In FY17, 70,306 cataract surgeries were performed. Overall, 44.4% of cataract surgeries were preceded by at least one low value preoperative test. The most common were ECG (26.4%), followed by complete blood count (26.1%), basic metabolic profile (17.5%), urinalysis (8.8%), chest x-ray (7.4%), and PFT (3.0%). Perhaps more interesting from a quality improvement perspective, large facility-level variation was found. In 126 major VHA facilities, the facility-level range of receiving at least one low value test was 6.3% to 98.4%, with 16 sites providing at least one low value test prior to 75% of cataract surgeries.
The principles of high-value, patient-centered health care demand that we avoid testing procedures that do not inform a patient's clinical management or outcomes, that can cause unintended harm, that waste their time, and that consume resources that might be used to improve the access and quality of care for them and other patients. This study has already identified an important de-implementation target, providing an opportunity to improve patient care while conserving resources for more beneficial uses.
External Links for this Project
Grant Number: I01HX002314-01A1
None at this time.